Sarepta Therapeutics
SRPT
189 hedge funds and large institutions have $1.44B invested in Sarepta Therapeutics in 2017 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 77 increasing their positions, 48 reducing their positions, and 23 closing their positions.
95% more call options, than puts
Call options by funds: $145M | Put options by funds: $74.3M
60% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 48
43% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 23
19% more capital invested
Capital invested by funds: $1.21B → $1.44B (+$233M)
6% more funds holding
Funds holding: 179 → 189 (+10)
3.34% more ownership
Funds ownership: 74.38% → 77.72% (+3.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$39.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$39.8M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$18.6M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$17.9M |
| 5 |
HM
HealthCor Management
New York
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
-$54.6M |
| 2 |
O
OrbiMed
New York
|
-$31.2M |
| 3 |
PA
Perceptive Advisors
New York
|
-$22.2M |
| 4 |
PP
PDT Partners
New York
|
-$10M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.42M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ECM
201
Ensemble Capital Management
San Francisco,
California
| – | -$296K | -10,000 | Closed |
|
202
Parallax Volatility Advisers
San Francisco,
California
| – | -$320K | -9,813 | Closed |
|
|
PAM
203
Princeton Alpha Management
Princeton Junction,
New Jersey
| – | -$270K | -9,106 | Closed |
|
|
AIM
204
Assured Investment Management
New York
| – | -$251K | -8,477 | Closed |
|
205
Dimensional Fund Advisors
Austin,
Texas
| – | -$210K | -7,079 | Closed |
|
206
SG Americas Securities
New York
| – | -$139K | -4,706 | Closed |
|
|
FAM
207
Fortaleza Asset Management
Chicago,
Illinois
| – | -$97K | -3,265 | Closed |
|
|
CLOS
208
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| – | -$24K | -800 | Closed |
|
|
SPIA
209
Steward Partners Investment Advisory
New York
| – | -$14K | -500 | Closed |
|
|
FMA
210
FNY Managed Accounts
New York
| – | -$8K | -300 | Closed |
|
|
MAM
211
Meeder Asset Management
Dublin,
Ohio
| – | -$3K | -103 | Closed |
|
SRPT Hedge Fund Activity: Q2 2017 in Review
189 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2017, worth a combined $1.44B — up 19% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new SRPT positions and 23 closed out — a net gain of 10 holders — while 77 added to existing stakes and 48 trimmed.
The largest buyer was Millennium Management, adding an estimated $39.9M. The largest seller was Carlson Capital, exiting entirely with an estimated $54.6M sold.
- 189 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2017, up from 179 in Q1 2017.
- Funds reported $1.44B of Sarepta Therapeutics stock for Q2 2017, up 19% quarter-over-quarter.
- 33 funds opened new Sarepta Therapeutics positions in Q2 2017 and 23 closed out, a net change of +10 holders.
- The largest Sarepta Therapeutics buyer in Q2 2017 was Millennium Management, an estimated $39.9M added.
- The largest Sarepta Therapeutics seller in Q2 2017 was Carlson Capital, an estimated $54.6M sold.
Based on aggregated 13F filings for Q2 2017.